BHW Bayerische Heilmittel Wissenschaften GmbH was founded with a clear vision: to bridge scientific innovation, regulatory excellence, and international market access across the pharmaceutical, medical device, and nutraceutical industries. Today, together with NAH – North American Heilmittel Inc. in Canada, the North American arm of the Heilmittel Group, the company provides integrated solutions covering product development, manufacturing, regulatory affairs, intellectual property, and international commercialization.

Active in more than 15 countries across Europe, North America, the Middle East, and China, the Heilmittel Group has built a portfolio of over 30 innovative healthcare products through GMP- and ISO-certified manufacturing facilities, serving hundreds of pharmacies, distributors, and healthcare partners worldwide. Among its flagship innovations are Cebedi^®, one of the first ultra-pure synthetic CBD platforms developed for the food supplement sector; EctoVelle^®, an innovative ectoin-based skincare range for eczema, psoriasis, and skin barrier disorders; and BHW Silicolgel^®, an advanced gastrointestinal solution for the management of irritable bowel syndrome (IBS) and digestive health. Scientific excellence is reinforced by the company’s experienced leadership team, including a Head of Medical Affairs holding a Ph.D., ensuring that every product is developed according to the latest scientific evidence and the highest international regulatory standards.

The company’s innovation-driven approach has earned international recognition. In 2025, BHW was named “Company of the Future” by the German Institute of Innovation (DiiD) in cooperation with DUP Unternehmer Magazine, and was also recognized by Food Business Review as one of the Top Food Supplement Manufacturers in Europe. Through scientific expertise, regulatory excellence, and premium healthcare innovations, the Heilmittel Group continues to strengthen its position as a trusted global partner for healthcare companies seeking sustainable growth and international expansion.

The Heilmittel Group, comprising BHW Bayerische Heilmittel Wissenschaften GmbH (Germany) and NAH – North American Heilmittel Inc. (Canada), continues to strengthen its international market credibility through active membership in leading industry organizations, including the Canadian Health Food Association (CHFA), the Chamber of Industry and Commerce (IHK) for Munich and Upper Bavaria, and the Bayern International business network. The Group’s commitment to scientific quality, regulatory excellence, and product integrity is further demonstrated by the recent listing of CollaMouv^® Athlete on the Kölner Liste^®, reinforcing its position as a trusted innovator in the global healthcare and nutraceutical sectors.

In an exclusive interview with Business Fortune, Mohamed Elsayyad, Head of Strategy & Marketing at Heilmittel Group, shared insights into how scientific innovation, regulatory expertise, and global partnerships are shaping the future of healthcare. He discussed BHW’s integrated approach to developing premium, science-based wellness solutions.

Interview Highlights

How do you identify emerging healthcare needs and translate them into science-backed solutions that deliver measurable value to customers?

Our innovation process begins by listening closely to healthcare professionals, pharmacists, distributors, and consumers across international markets. As part of the Heilmittel Group, which includes BHW Bayerische Heilmittel Wissenschaften GmbH (BHW) in Germany and NAH North American Heilmittel Inc. (NAH) in Canada, we benefit from valuable market insights across Europe and North America. This global perspective enables us to identify emerging healthcare needs and evolving consumer trends.

Unlike many service providers who focus only on manufacturing or regulatory affairs, BHW integrates scientific development, regulatory strategy, intellectual property protection, manufacturing coordination, and international commercialization under one platform.

By combining scientific innovation, regulatory expertise, and international market knowledge, the Heilmittel Group transforms innovative ideas into clinically relevant and commercially successful products. Whether through private label supplement development, contract manufacturing, or end-to-end product commercialization, our mission is to deliver premium healthcare solutions that create lasting value for our partners and consumers worldwide.

Moreover, we are increasingly leveraging digital technologies and artificial intelligence to enhance formulation research, regulatory intelligence, and market analysis.

BHW provides a wide range of services, from product development and manufacturing to regulatory support. How do these integrated services help clients bring high-quality healthcare products to market more efficiently?

We offer a comprehensive end-to-end solution that covers every stage of healthcare product development and commercialization. Our services include product development, formulation, regulatory affairs, artwork development, manufacturing coordination, quality management, international product registration, branding, commercialization support, and intellectual property assistance. Through our experienced regulatory and legal teams, we also help customers and business partners secure trademark registrations and protect their brands across key international markets.

This integrated approach significantly reduces development timelines, streamlines project management, and enables our partners to efficiently launch premium healthcare products across multiple global markets with confidence.

As healthcare becomes increasingly globalized, partnerships play a critical role in expanding access to innovative wellness solutions. How has the Heilmittel Group strengthened BHW’s international reach, and what opportunities do you see for growth in new markets?

The establishment of the Heilmittel Group marked an important milestone in our international expansion strategy.

Today, the Group brings together BHW Bayerische Heilmittel Wissenschaften GmbH in Germany and NAH-North American Heilmittel Inc. in Canada, creating a strong platform to serve customers across Europe and North America while supporting continued global market expansion.

As members of the Canadian Health Food Association (CHFA) and the IHK for Munich and Upper Bavaria (Industrie- und Handelskammer für München und Oberbayern), we remain actively engaged with leading industry organizations that promote innovation, regulatory excellence, and international trade. These memberships enhance our ability to support customers through improved market access, regulatory insights, and strategic business development opportunities.

In addition, we have built a growing network of trusted local business partners and distributors across several Middle Eastern markets. This network enables us to provide regional expertise, regulatory support, and efficient commercialization strategies tailored to the specific needs of each market.

Looking ahead, we see significant opportunities to further expand the Heilmittel Group across Europe, North America, the Middle East, and selected Asian markets through innovation, strategic partnerships, and science-based healthcare solutions.

Sustainability is becoming increasingly important in healthcare manufacturing. How is BHW integrating environmentally responsible practices into its operations?

Sustainability is becoming increasingly important across the healthcare industry. We actively collaborate with manufacturing partners who are committed to internationally recognized environmental and quality standards while continuously exploring innovative packaging solutions, responsible sourcing strategies, and efficient production processes.

At the same time, we believe sustainability goes beyond environmental responsibility. It also means creating products that enhance people’s quality of life while maintaining ethical and responsible business practices throughout the entire value chain.

BHW has received industry recognition for its innovation and manufacturing excellence. Which recent achievement are you most proud of, and what impact has it had on the company?

Several milestones stand out. Our partnership with the Kölner Liste^® reflects our commitment to providing trusted products for athletes and professionals through our CollaMouv Athlete product line. Another significant achievement is the expansion of the Heilmittel Group into Canada through NAH - North American Heilmittel Inc., along with its recent membership in the Canadian Health Food Association (CHFA), which strengthens our international presence. These accomplishments highlight our strategy of combining scientific innovation with global market expansion.

Looking ahead, what is your vision for BHW over the next five years, and how do you plan to contribute to the advancement of the global healthcare and wellness industry?

Our vision is to establish Heilmittel Group as one of the most respected international healthcare companies, specializing in science-based nutraceuticals, medical devices, and innovative wellness solutions.

Over the next five years, we aim to strengthen our presence across Europe and North America while expanding into carefully selected global markets through strategic partnerships.

We will continue investing in research, regulatory excellence, digital transformation, and product innovation to deliver impactful healthcare solutions that enhance people’s lives worldwide.

Under the Vision of Mohamed Elsayyad

Mohamed Elsayyad is originally a pharmacist holding PharmD and MBA degrees and is currently pursuing a Master of Political Science at the University of Ottawa, Canada. His multidisciplinary background brings together scientific expertise, business leadership, public-health advocacy, and policy knowledge, enabling him to approach the global healthcare industry from both commercial and societal perspectives.

Before entering the entrepreneurial sector, Mohamed spent nine years at GlaxoSmithKline (GSK), where he held several roles within the Vaccinology Division. During this period, he developed extensive experience in the pharmaceutical industry, immunization, public health, and strategic healthcare initiatives. He was also actively involved in advocating for vaccines and participated in several public-awareness campaigns aimed at increasing understanding of immunization, addressing misconceptions, and promoting the importance of vaccination in protecting individuals and communities.

Today, Mohamed serves as Head of Strategy & Marketing at BHW Bayerische Heilmittel Wissenschaften GmbH in Germany and NAH – North American Heilmittel Inc. in Canada. In this role, he leads the Heilmittel Group’s global strategy, international expansion, brand development, and strategic partnerships across Europe, North America, the Middle East, and other international markets.

Through his leadership, the Heilmittel Group continues to expand its global footprint by developing and commercializing science-based healthcare solutions, strengthening regulatory excellence, and building sustainable relationships with healthcare organizations, manufacturers, distributors, pharmacies, and business partners worldwide.

Driven by a passion for scientific advancement, healthcare innovation, and responsible business growth, Mohamed is committed to positioning the Heilmittel Group as a globally recognized healthcare organization delivering premium, evidence-based healthcare and wellness solutions while contributing positively to public health and patient well-being.

“The future of healthcare belongs to companies that combine science, innovation, and global collaboration. At the Heilmittel Group, we will continue investing in research, regulatory excellence, digital transformation, and strategic partnerships to develop innovative healthcare solutions that improve lives, empower our partners, and create sustainable value for patients worldwide.”